Regional application of TNFα in the treatment of cancer: A preclinical-clinical interactive program

Journal of Inflammation

Volumn 47, Issue 1-2, 1995, Pages 104-113

  Eggermont, Alexander M M ^a   Manusama, Eric R ^a   Ten Hagen, Timo L M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Clinical; Limb; Liposomes; Liver; Preclinical; Regional perfusion; Tnf ; Tumor models

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; DRUG TARGETING; LIMB PERFUSION; MELANOMA; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; HUMANS; NEOPLASMS; PERFUSION; PROGRAM DEVELOPMENT; RATS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029548867     PISSN: 10787852     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Liénard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ: High-dose recombinant tumor necrosis factor alpha in combination with Interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10:50-62, 1992.
2. Lejeune FJ, Liénard D, Leyvraz S, Mirimanoff RO: Regional therapy of melanoma. Eur J Cancer 29A:606-612, 1993.
3. Eggermont AMM, Liénard D, Schraffordt Koops H, Kroon BBR, Rosenkaimer F, Klaase JM, Schmilz RIM, Lejeune FJ: High dose TNFcx in isolation perfusion of the limb: Highly effective treatment for melanoma in transit métastases and unresectable sarcomas. Reg Cancer Treat 8:32-36, 1995.
4. Liénard D, Eggermont AMM, Schraffordt Koops H, Kroon BBR, Lejeune FJ: TNF in isolated limb perfusion for treatment of locally advanced melanoma. Eur Cytokine Netw 7:299, 1996.
5. Fraker DL: Regional TNF perfusion of the limb and liver clinical results and mechanisms of action. Eur Cytokine Netw 7:286, 1996.
6. Eggermont AMM, Schraffordt Koops H, Lienard D, Kroon BBR, van Geel AN, Hoekstra HJ, Lejeune FJ: Isolated limb perfusion with high dose tumor necrosis factoroc in combination with IFNy and melphalan for irresectable extremity soft tissue sarcomas: A multicenter trial. J Clin Oncol 14:(0ctober) 1996.
7. Eggermont AMM, Schraffordt Koops H, Klausner JM, Schlag PM, Kroon BBR, Ben-Ari G, Lejeune FJ: High dose TNFa in isolation perfusion of the limb: Highly effective treatment for melanoma in transit métastases and unresectable sarcomas. In Pinedo H, Suit H, Verweij J (eds): "New Developments in the Treatment of Soft Tissue Sarcoma." Amsterdam: Kluwer Academics (in press).
8. Eggermont AMM, Schraffordt Koops H, Lienard D, Lejeune FJ, Oukerk M: Angiographie observations before and after high dose TNF isolated limb perfusion in patients with extremity soft tissue sarcomas. Eur J Surg Oncol 1994;20:323.
9. Sijens PE, Eggermont AMM, Van Dijk P, Oudkerk M: 31P magnetic resonance spectroscopy as predictor for clinical response in human extremity sarcomas treated by single dose TNFa + melphalan isolated limb perfusion. NMR Biomedicine 18:215-224, 1995.
10. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B: An endotoxin induced serum factor that causes necrosis of tumors. Proc Natl Acad Sei USA 72:3666-3370, 1975.
11. Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Shepard HM: Recombinant tumor necrosis factor-alpha: Effects on proliferation of normal and transformed cells in vitro. Science 230:943-945, 1985.
12. Renard N, Lienard D, Lespagnard L, Eggermont AMM, Heimann R, Lejeune FJ: Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (TNFa). Int J Cancer 57:656-663, 1994.
13. Renard N, Nooijen PTGA, Schalkwijk L, DeWaal RMW, Eggermont AMM, Lienard 0, Kroon BBR, Lejeune FJ, Ruiter DJ: VWF release and platelet aggregation in human melanoma after perfusion with TNFa. J Pathol 176:279-287, 1995.
14. Nooijen PTGA, Eggermont AMM, Verbeek MM, Schalkwijk L, Buurman WA, DeWaal RMW, Ruiter DJ: Transient induction of E-selectin expression following TNFbased isolated limb perfusion in melanoma and sar-coma patients is not tumor specific. J Immunother 19:33-44, 1996.
15. Watanabe N, Niitsu Y, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M, Urushizaki I: Toxic effect of TNF on tumor vasculature in mice. Cancer Res 49:2179-2183, 1988.
16. Sato N, Goto T, Haranaka K, Satomi N, Nariuchi H, Mano-Hirano Y, Sawasaki Y: Actions of TNF on cultured vascular endothelial cells: Morphological modulation, growth inhibition and cytotoxicity. J Natl Cancer Inst 76:1113-1117, 1986.
17. Bloksma N, van de Wiel PA, Kuper CF, Hofhuis FMA: Multiple facets of induction of tumor necrosis. Ann Inst Pasteur/lmmunol 139:294-299,1988.
18. Nawroth P, Handley D, Matsueda G, DeWaal G, Gerlach H, Blohm D, Stern D: TNF/cachectin-induced intravascular fibrin formation in Meth-A fibrosarcomas. J Exp Med 168:637-647, 1988.
19. Kort WJ, Zondervan PE, Hulsman LOM, Wijma IM, Westbroek DL: Incidence of spontaneous tumors in a group of retired breeder female Brown Norway rats. J Natl Cancer Inst 72:709-713, 1984.
20. Kort WJ, Zondervan PE, Hulsman LOM, van Schalkwijk WP, Wijma IM, Westbroek DL: Spontaneous tumor incidence in female Brown Norway rats after lifelong diets high and low in linoleic acid. J Natl Cancer Inst 74:529-436, 1985.
21. Barendsen, GW, Janse HC: Differences in effectiveness of combined treatments with ionizing radiation and vinblastine, evaluated for experimental sarcomas and squamous cell carcinomas in rats. Int J Radiât Oncol Biol Phys 4:95-102, 1978.
22. Manusama ER, Durante NMC, Marquet RL, Eggermont AMM: Ischemia promotes the antitumor effect of tumor necrosis factor alpha (TNFa) in isolated limb perfusion in the rat. Reg Cancer Treat 7:155-159, 1994.
23. Manusama ER, Nooijen PTGA, Stavast J, Durante NMC, Marquet RL, Eggermont AMM: Synergistic antitumour effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat. Br J Surg 83:551-555, 1996.
24. Manusama ER, Stavast J, Durante NMC, Marquet RL, Eggermont AMM: Isolated limb perfusion in a ratosteosarcoma model: A new anti-tumour approach. Eur J Surg Oncol 22:152-157, 1996.
25. Asher A, Mule JJ, Reichert CM, Shiloni E, Rosenberg SA: Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138:963-974, 1987.
26. Posner M, Liénard D, Lejeune FJ, Rosenfelder D, Kirkwood JM: Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor (TNF) alone for metastatic intransit melanoma. Proc Am Soc Clin Oncol 13:1351, 1994.
27. Nooijen PTGA, Manusama ER, Schalkwijk L, de Waal RMW, Eggermont AMM, Ruiter DJ: Histopathologic analysis of the synergistic antitumour effects of TNFα and melphalan in an isolated limb perfusion model of rat sarcoma. Br J Cancer (in press).
28. Manda T, Nishigaki F, Mukumoto S, Masuda K, Nakamura T, Shimomura K: The efficacy of combined treatment with recombinant human tumor necrosis factora and 5-fluorouracil is dependent on the development of capillaries in tumor. Eur J Cancer 26:93-99, 1990.
29. Mule JJ, Asher A, Mclntosh J, Lafreniere R, Shiloni E, Lefor A, Reichert CM, Rosenberg SA: Antitumor effect of recombinant tumor necrosis factor-a against murine sarcomas at visceral sites: Tumor size influences the response to therapy. Cancer Immunol Immunother 26:202-208, 1988.
30. Weidner N, Folkman J: Tumor vascularity as a prognostic factor in cancer. In DeVita VT, Hellman S, Rosenberg SA (eds): "Important Advances in Oncology." Philadelphia: Lippincott-Raven Publishers, 1996, pp. 167-190.
31. Schear MJ: Chemical treatment of tumors. IX. Reactions of mice with primary subcutaneous tumors to injection of a hemorrhage-producing bacterial polysaccharide. J Natl Cancer Inst 4:461-476, 1944.
32. Parr I, Wheeler E, Alexander P: Similarities of the antitumor actions of endotoxin, lipid A and double stranded RNA. Br J Cancer 27:370-389, 1973.
33. Dvorak HF: Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing [review]. N Engl J Med 315:1650-1659, 1986.
34. Jain RK: Barriers to drug delivery in solid tumors. Sei Am 271:58-65, 1994.
35. Jain RK: Delivery of molecular medicine to solid tumors. Science 271:1079-1080, 1996.
36. Salmon SE, Yong L, Scuderi P, Clark B: Antineoplastic effects of tumor necrosis factof a alone and in combination wiht recombinant gamma-interfeon on tumor biopties in clonogenic assay. J Clin Oncol 5:1816-1821, 1987.
37. Schiller JH, Bittner G, Storer B, Wilson JKV: Synergistic antitumor effects of tumor necrosis factor a and gamma-interferon on human colon carcinoma cell lines. Cancer Res 47:2809-2813, 1987.
38. Brouckaert PGG, Leroux-Rouls GG, Guisez Y, Tavernier J, Fiers W: In vivo anti-tumor activity of recombinant human and murine TNF, alone and in combination with IFN-gamma on a syngeneic murine melanoma. Int J Cancer 38:763-769, 1986.
39. Manusama ER, Stavast J, Marquet RL, Eggermont AMM: Total body irradiation (TBI) attenuates antitumor effects of TNFα in isolated limb perfusions (ILP) in the rat. Eur J Surg Res 27(S1):110, 1995.
40. Manusama ER, Durante NMC, Marquet RL, Eggermont AMM: Nitric oxide inhibition enhances the antitumor effects of TNFa in an isolated limb perfusion (ILP) model in the rat. Eur J Surg Res 27(S1):79, 1995.
41. Progrebniak HW, Witt CJ, Terrill R, Kranda K, Travis WD, Rosenberg SA, Pass HI: Isolated lung perfusion with tumor necrosis factor: A swine model in preparation of human trials. Ann Thorac Surg 57:1477-1483, 1994.
42. Fraker DL, Alexander HR, Thorn AK: Use of tumor necrosis factor in isolated hepatic perfusion. Circul Shock 44:45-50, 1994.
43. Vries de MR, Borel Rinkes IHM, Wiggers T, Jonker AM, Weijers-Hille MJ, Eggermont AMM: Hyperthermic isolated hepatic perfusion with TNFoc with and without melphalan in pigs. Eur J Surg Res 27(S1):81, 1995.
44. Veen van de AH, Manusama ER, Kämpen van ÇA, Durante NMC, Marquet RL, Eggermont AMM: Tumor Necrosis Factor-a (TNFa) in isolated kidney perfusions in rats: toxicity and antitumor effects. Eur J Surg Oncol 20:404-405, 1994.
45. Vries de MR, Borel Rinkes IHM, Hack CE, Wiggers Th, Van de Velde CJH, Kuppen PJK, Eggermont AMM: Isolated hepatic perfusion with TNFa and Melphalan: Local and systemic effects on secondary cytokine release, coagulation and fibrinolysis. Eur J Surg Res 27(S1):109, 1995.
46. Vries de MR, Borel Rinkes IHM, Buurman WA, Wiggers Th, VandeVelde CJH, Eggermont AMM: Soluble TNFa receptors induction by isolated hepatic perfusion with TNFa and melphalan. Eur J Surg Res 27(S1):108,1995.
47. Kuppen PJK, Jonges LE, VandeVelde CJH, Vahrmeijer AL, Tollenaar RAEM, Borel Rinkes IHM, Eggermont AMM: Liver and tumour tissue concentrations of TNFa in cancer patients treated with TNFa and melphalan by isolated liver perfusion. Br J Cancer in press, 1996.
48. Kahky MP, Daniel CO, Cruz AB, Gaskill HV: Portal infusion of tumor necrosis factor increases mortality in rats. J Surg Res 49:138-145, 1990.
49. Dvorak HF, Brown LF, Detmat M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029-1039, 1995.
50. Jain RK: Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 47, 559-593, 1987.
51. Jain RK: Whitaker Lecture: Delivery of Molecules, Particles, and Cells to Solid Tumors. Ann Biochem Engeneering 24:457-473, 1995.
52. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK: Microvasculature permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 54:3352-3356, 1994.
53. Gullino PM: Techniques in tumor pathophysiology. In Busch H (ed): "Methods in Cancer Research." New York: Academic Press, 1970. pp. 45-92.
54. Huang SK, Lee K-D, Hong K, Friend DS, Papahadjopoulos D: Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 52: 5135-5143, 1992.
55. Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D: Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 52:6774-6781,1992.
56. Klibanov AL, Murayama K, Torchilin VP, Huang L: Amphipathic polyethylene-glycols effectively prolong the circulation time of liposomes. FEBS Lett 268:235-237, 1990.
57. Lasic DD, Martin FJ, Gabizon A, Huang SK, Papahadjopoulos D: Sterically stabilized liposomes: A hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1070:187-192,1991.
58. Vaage J, Donovan D, Mayhew E, Abra R, Huang A: Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 72:3671-3675, 1993.
59. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW: Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res 53:3765-3770, 1993.
60. Woodle MC, Lasic DD: Sterically stabilized liposomes. Biochim Biophys Acta 1113:171-199, 1992.
61. Allen TM: Long circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sei 15:215-229, 1994.
62. Kim S: Liposomes as carries of cancer chemotherapy: Current status future prospects. Drug 46:618-638,1993.
63. Williams SS, Alosco TR, Mayhew E, Lasic DD, Martin FJ, Bankert RB: Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res 53:3964-3967, 1993.
64. Cowens JW, Creaven PJ, Greco WR, Brenner DE, Tung Y, Ostro M, Pilkiewicz F, Ginsberg R, Petrelli N: Initial clinical (Phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res 53:2796-2802, 1993.
65. Veen van der AH, ten Hagen TLM, Marquet RL, Eggermont AMM: Treatment of solid limb tumors with liposome-encapsulated tumor necrosis factor-a in the rat. Proc Am Assoc Cancer Res 37:483, 1996.
66. Duzgunes N, Perumal VK, Brunette EN, Gangadharam PRJ, Debs RJ: Treatment of Mycobacterium avium complex infections by free and liposome-encapsulated tumor necrosis factor-alpha (Cachectin): Studies on peritoneal macrophages and the beige mouse model. In Lopez-Berestein G, Fidler U (eds): "Liposomes in the Therapy of Infectious Disease and Cancer." Symposium on Molecular and Cellular Biology, UCLA. New York: Alan R. Liss. Inc., New Series, 1989, vol. 89, pp. 287-294.
67. Debs RJ, Fuchs HJ, Philip R, Brunette EN, Duzgunes N, Shellito JE, Liggitt D, Patton JR: Immunomodulatory and toxic effects of free and liposome-encapsulated tumor necrosis factor a in rats. Cancer Res 50:375380, 1990.
68. Gatanaga T, Noguchi K, Tanabe Y, Inagawa H, Soma G-l, Mizuno D: Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (rTNFS) with less toxicity than conventional rTNFa in vivo. J Biol Resp Modif 8:278-286, 1989.
69. Lodato RF, Feig B, Akimaru K, Soma G-l, Kloostergaard J: Hemodynamic evaluation of recombinant human tumor necrosis factor (TNF)-a, TNF-SAM? and liposomal TNF-SAM2 in an anesthetized dog model. J Immunother 17:19-29, 1995.
70. Akimaru K, Auzenne E, Akimaru Y, Leroux ML, Hayman AC, Utsumi T, Soma Gl, Klostergaard J: Formulation and antitumor efficacy of liposomal-caprylated-TNFSAM2Cytokines Mol Therapy 1:197-210, 1995.
71. Van Ostade X, Vandenabeele P, Everaerdt B, Fiers W: Human TNF mutants with selective activity on the p55 receptor. Nature 361:266-269, 1993.
72. Loetscher H, Stueber D, Banner D, Mackay F, Lesslauer W: Human tumor necrosis factor a (TNFa) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. J Biol Chem 268:26350-26357, 1993.
73. Miyata K, Kato M, Nishimura K, Sakae N, Kawagoe K, Nishikawa T, Kuroda K, Yamaguchi K, Aoyama Y, Mitsuishi Y, Yamada N: A YIGSR-containing novel mutein without the detrimental enhancing effect of human TNFa of enhancing experimental pulmonary metastasis. Clin Exp Metastasis 10:267-272, 1992.
74. Shikama H, Miyata K, Sakae N, Muitsuishi Y, Nishimura K, Kuroda K, Kato M: Novel mutein of tumor necrosis factor (F4614) with reduced hypotensive effect. J Interf Cytok Res 15:677-684, 1995.
75. Miyata K, Mitsuishi Y, Shikama H, Sakae N, Nishimura K, Sakae N, Kato M: Overcoming the metastasis-enhancing potential of human TNF by introducing the celladhesive Arg-Gly-Asp sequence. J Interf Cytok Res 15:161-169, 1995.
76. Kuroda K, Miyata K, Shikama H, Kawagoe T, Nishimura K, Takeda K, Sakae N, Sakae N, Kato M: Novel muteins of human tumor necrosis factor with potent antitumor activity and less lethal toxicity in mice. Int J Cancer 63:152-157, 1995.
77. Lejeune FJ, Lienard D, Eggermont A, Koops Shraffordt H, Kroon B, Gerain J, Rosenkaimer F, Schmilz P: Experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma. Circul Shock 43:191-197, 1994.